nodes	percent_of_prediction	percent_of_DWPC	metapath
Trisalicylate-choline—PTGS2—urinary bladder cancer	0.587	1	CbGaD
Trisalicylate-choline—PTGS2—Cisplatin—urinary bladder cancer	0.0978	0.356	CbGbCtD
Trisalicylate-choline—PTGS2—Etoposide—urinary bladder cancer	0.0961	0.349	CbGbCtD
Trisalicylate-choline—PTGS1—Etoposide—urinary bladder cancer	0.0811	0.295	CbGbCtD
Trisalicylate-choline—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00154	0.0505	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	0.00142	0.0467	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00122	0.0401	CbGpPWpGaD
Trisalicylate-choline—Magnesium salicylate—PTGS2—urinary bladder cancer	0.00118	0.54	CrCbGaD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00104	0.0343	CbGpPWpGaD
Trisalicylate-choline—Salsalate—PTGS2—urinary bladder cancer	0.00101	0.459	CrCbGaD
Trisalicylate-choline—Oesophagitis—Fluorouracil—urinary bladder cancer	0.000844	0.00814	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Cisplatin—urinary bladder cancer	0.000836	0.00806	CcSEcCtD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000829	0.0272	CbGpPWpGaD
Trisalicylate-choline—Pruritus—Valrubicin—urinary bladder cancer	0.000814	0.00785	CcSEcCtD
Trisalicylate-choline—Hypothermia—Epirubicin—urinary bladder cancer	0.000802	0.00774	CcSEcCtD
Trisalicylate-choline—Body temperature decreased—Epirubicin—urinary bladder cancer	0.000802	0.00774	CcSEcCtD
Trisalicylate-choline—Confusional state—Mitomycin—urinary bladder cancer	0.000799	0.0077	CcSEcCtD
Trisalicylate-choline—Oedema—Mitomycin—urinary bladder cancer	0.000792	0.00764	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Valrubicin—urinary bladder cancer	0.000787	0.00759	CcSEcCtD
Trisalicylate-choline—Shock—Mitomycin—urinary bladder cancer	0.000779	0.00752	CcSEcCtD
Trisalicylate-choline—Gastric ulcer—Epirubicin—urinary bladder cancer	0.000774	0.00746	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Etoposide—urinary bladder cancer	0.000766	0.00739	CcSEcCtD
Trisalicylate-choline—Deafness—Gemcitabine—urinary bladder cancer	0.000762	0.00735	CcSEcCtD
Trisalicylate-choline—Dizziness—Valrubicin—urinary bladder cancer	0.00076	0.00733	CcSEcCtD
Trisalicylate-choline—Anorexia—Mitomycin—urinary bladder cancer	0.000755	0.00728	CcSEcCtD
Trisalicylate-choline—Hypothermia—Doxorubicin—urinary bladder cancer	0.000742	0.00716	CcSEcCtD
Trisalicylate-choline—Body temperature decreased—Doxorubicin—urinary bladder cancer	0.000742	0.00716	CcSEcCtD
Trisalicylate-choline—Oesophagitis—Etoposide—urinary bladder cancer	0.000733	0.00707	CcSEcCtD
Trisalicylate-choline—PTGS1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000732	0.024	CbGpPWpGaD
Trisalicylate-choline—Vomiting—Valrubicin—urinary bladder cancer	0.000731	0.00705	CcSEcCtD
Trisalicylate-choline—Rash—Valrubicin—urinary bladder cancer	0.000725	0.00699	CcSEcCtD
Trisalicylate-choline—Dermatitis—Valrubicin—urinary bladder cancer	0.000724	0.00699	CcSEcCtD
Trisalicylate-choline—Headache—Valrubicin—urinary bladder cancer	0.00072	0.00695	CcSEcCtD
Trisalicylate-choline—Gastric ulcer—Doxorubicin—urinary bladder cancer	0.000716	0.0069	CcSEcCtD
Trisalicylate-choline—Deafness—Cisplatin—urinary bladder cancer	0.000711	0.00685	CcSEcCtD
Trisalicylate-choline—Somnolence—Mitomycin—urinary bladder cancer	0.000704	0.00679	CcSEcCtD
Trisalicylate-choline—Burning sensation—Methotrexate—urinary bladder cancer	0.000692	0.00667	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Mitomycin—urinary bladder cancer	0.000689	0.00664	CcSEcCtD
Trisalicylate-choline—Lethargy—Fluorouracil—urinary bladder cancer	0.000684	0.0066	CcSEcCtD
Trisalicylate-choline—Nausea—Valrubicin—urinary bladder cancer	0.000683	0.00659	CcSEcCtD
Trisalicylate-choline—Pain—Mitomycin—urinary bladder cancer	0.000677	0.00653	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000665	0.0218	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Mitomycin—urinary bladder cancer	0.000653	0.0063	CcSEcCtD
Trisalicylate-choline—Burning sensation—Epirubicin—urinary bladder cancer	0.000647	0.00624	CcSEcCtD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000647	0.0212	CbGpPWpGaD
Trisalicylate-choline—Stupor—Methotrexate—urinary bladder cancer	0.000644	0.00621	CcSEcCtD
Trisalicylate-choline—Weight increased—Thiotepa—urinary bladder cancer	0.000638	0.00615	CcSEcCtD
Trisalicylate-choline—Burning sensation—Doxorubicin—urinary bladder cancer	0.000599	0.00578	CcSEcCtD
Trisalicylate-choline—Epistaxis—Thiotepa—urinary bladder cancer	0.000589	0.00568	CcSEcCtD
Trisalicylate-choline—Hallucination—Thiotepa—urinary bladder cancer	0.000558	0.00538	CcSEcCtD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000556	0.0183	CbGpPWpGaD
Trisalicylate-choline—Stinging—Epirubicin—urinary bladder cancer	0.000555	0.00535	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Mitomycin—urinary bladder cancer	0.000542	0.00523	CcSEcCtD
Trisalicylate-choline—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.000536	0.0176	CbGpPWpGaD
Trisalicylate-choline—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.000527	0.00508	CcSEcCtD
Trisalicylate-choline—Dizziness—Mitomycin—urinary bladder cancer	0.000524	0.00505	CcSEcCtD
Trisalicylate-choline—Tinnitus—Thiotepa—urinary bladder cancer	0.000523	0.00504	CcSEcCtD
Trisalicylate-choline—Stinging—Doxorubicin—urinary bladder cancer	0.000514	0.00495	CcSEcCtD
Trisalicylate-choline—Sweating—Gemcitabine—urinary bladder cancer	0.000504	0.00486	CcSEcCtD
Trisalicylate-choline—Vomiting—Mitomycin—urinary bladder cancer	0.000504	0.00486	CcSEcCtD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000503	0.0165	CbGpPWpGaD
Trisalicylate-choline—Rash—Mitomycin—urinary bladder cancer	0.0005	0.00482	CcSEcCtD
Trisalicylate-choline—Dermatitis—Mitomycin—urinary bladder cancer	0.000499	0.00481	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000498	0.0164	CbGpPWpGaD
Trisalicylate-choline—Headache—Mitomycin—urinary bladder cancer	0.000496	0.00479	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Epirubicin—urinary bladder cancer	0.000491	0.00474	CcSEcCtD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.00049	0.0161	CbGpPWpGaD
Trisalicylate-choline—Erythema—Thiotepa—urinary bladder cancer	0.000488	0.00471	CcSEcCtD
Trisalicylate-choline—Epistaxis—Fluorouracil—urinary bladder cancer	0.000487	0.0047	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.000472	0.0155	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.000472	0.0155	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000472	0.0155	CbGpPWpGaD
Trisalicylate-choline—Nausea—Mitomycin—urinary bladder cancer	0.000471	0.00454	CcSEcCtD
Trisalicylate-choline—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.000464	0.00447	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Methotrexate—urinary bladder cancer	0.000459	0.00442	CcSEcCtD
Trisalicylate-choline—Hypocalcaemia—Doxorubicin—urinary bladder cancer	0.000454	0.00438	CcSEcCtD
Trisalicylate-choline—Injection site reaction—Epirubicin—urinary bladder cancer	0.000447	0.00431	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000446	0.0043	CcSEcCtD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000441	0.0145	CbGpPWpGaD
Trisalicylate-choline—Ecchymosis—Methotrexate—urinary bladder cancer	0.000434	0.00419	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000432	0.0142	CbGpPWpGaD
Trisalicylate-choline—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000429	0.00414	CcSEcCtD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.00042	0.0138	CbGpPWpGaD
Trisalicylate-choline—Injection site reaction—Doxorubicin—urinary bladder cancer	0.000414	0.00399	CcSEcCtD
Trisalicylate-choline—Oesophagitis—Epirubicin—urinary bladder cancer	0.000411	0.00396	CcSEcCtD
Trisalicylate-choline—Erythema—Gemcitabine—urinary bladder cancer	0.000411	0.00396	CcSEcCtD
Trisalicylate-choline—Tinnitus—Cisplatin—urinary bladder cancer	0.00041	0.00395	CcSEcCtD
Trisalicylate-choline—Flushing—Cisplatin—urinary bladder cancer	0.000408	0.00394	CcSEcCtD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000407	0.0134	CbGpPWpGaD
Trisalicylate-choline—Ecchymosis—Epirubicin—urinary bladder cancer	0.000407	0.00392	CcSEcCtD
Trisalicylate-choline—Erythema—Fluorouracil—urinary bladder cancer	0.000404	0.00389	CcSEcCtD
Trisalicylate-choline—Confusional state—Thiotepa—urinary bladder cancer	0.000402	0.00387	CcSEcCtD
Trisalicylate-choline—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000397	0.00383	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000389	0.0128	CbGpPWpGaD
Trisalicylate-choline—Erythema—Cisplatin—urinary bladder cancer	0.000383	0.00369	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Etoposide—urinary bladder cancer	0.000381	0.00367	CcSEcCtD
Trisalicylate-choline—Oesophagitis—Doxorubicin—urinary bladder cancer	0.00038	0.00367	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00038	0.0125	CbGpPWpGaD
Trisalicylate-choline—Anorexia—Thiotepa—urinary bladder cancer	0.00038	0.00366	CcSEcCtD
Trisalicylate-choline—Ecchymosis—Doxorubicin—urinary bladder cancer	0.000376	0.00363	CcSEcCtD
Trisalicylate-choline—Flushing—Etoposide—urinary bladder cancer	0.000374	0.00361	CcSEcCtD
Trisalicylate-choline—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000368	0.0121	CbGpPWpGaD
Trisalicylate-choline—Lethargy—Methotrexate—urinary bladder cancer	0.000356	0.00343	CcSEcCtD
Trisalicylate-choline—Somnolence—Thiotepa—urinary bladder cancer	0.000354	0.00342	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Thiotepa—urinary bladder cancer	0.000351	0.00338	CcSEcCtD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000349	0.0115	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.000348	0.0114	CbGpPWpGaD
Trisalicylate-choline—Decreased appetite—Thiotepa—urinary bladder cancer	0.000346	0.00334	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Etoposide—urinary bladder cancer	0.000343	0.00331	CcSEcCtD
Trisalicylate-choline—Constipation—Thiotepa—urinary bladder cancer	0.000341	0.00329	CcSEcCtD
Trisalicylate-choline—Pain—Thiotepa—urinary bladder cancer	0.000341	0.00329	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000336	0.011	CbGpPWpGaD
Trisalicylate-choline—Oedema—Gemcitabine—urinary bladder cancer	0.000335	0.00323	CcSEcCtD
Trisalicylate-choline—Lethargy—Epirubicin—urinary bladder cancer	0.000333	0.00321	CcSEcCtD
Trisalicylate-choline—Confusional state—Fluorouracil—urinary bladder cancer	0.000332	0.0032	CcSEcCtD
Trisalicylate-choline—Oedema—Fluorouracil—urinary bladder cancer	0.00033	0.00318	CcSEcCtD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000329	0.0108	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000328	0.00317	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000324	0.00312	CcSEcCtD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000323	0.0106	CbGpPWpGaD
Trisalicylate-choline—Anorexia—Gemcitabine—urinary bladder cancer	0.000319	0.00308	CcSEcCtD
Trisalicylate-choline—Urticaria—Thiotepa—urinary bladder cancer	0.000317	0.00305	CcSEcCtD
Trisalicylate-choline—Anorexia—Fluorouracil—urinary bladder cancer	0.000314	0.00303	CcSEcCtD
Trisalicylate-choline—Hypotension—Gemcitabine—urinary bladder cancer	0.000313	0.00302	CcSEcCtD
Trisalicylate-choline—Oedema—Cisplatin—urinary bladder cancer	0.000312	0.00301	CcSEcCtD
Trisalicylate-choline—Lethargy—Doxorubicin—urinary bladder cancer	0.000308	0.00297	CcSEcCtD
Trisalicylate-choline—Hypotension—Fluorouracil—urinary bladder cancer	0.000308	0.00297	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000302	0.00291	CcSEcCtD
Trisalicylate-choline—Asthma—Methotrexate—urinary bladder cancer	0.000301	0.00291	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000298	0.00288	CcSEcCtD
Trisalicylate-choline—Somnolence—Gemcitabine—urinary bladder cancer	0.000298	0.00287	CcSEcCtD
Trisalicylate-choline—Anorexia—Cisplatin—urinary bladder cancer	0.000298	0.00287	CcSEcCtD
Trisalicylate-choline—Somnolence—Fluorouracil—urinary bladder cancer	0.000293	0.00283	CcSEcCtD
Trisalicylate-choline—Hypotension—Cisplatin—urinary bladder cancer	0.000292	0.00282	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000291	0.00281	CcSEcCtD
Trisalicylate-choline—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000291	0.00957	CbGpPWpGaD
Trisalicylate-choline—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00029	0.0028	CcSEcCtD
Trisalicylate-choline—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000289	0.00279	CcSEcCtD
Trisalicylate-choline—Confusional state—Etoposide—urinary bladder cancer	0.000289	0.00278	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000288	0.00945	CbGpPWpGaD
Trisalicylate-choline—Pain—Gemcitabine—urinary bladder cancer	0.000287	0.00276	CcSEcCtD
Trisalicylate-choline—Constipation—Gemcitabine—urinary bladder cancer	0.000287	0.00276	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000286	0.00276	CcSEcCtD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000285	0.00935	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000283	0.00931	CbGpPWpGaD
Trisalicylate-choline—Asthma—Epirubicin—urinary bladder cancer	0.000282	0.00272	CcSEcCtD
Trisalicylate-choline—Pruritus—Thiotepa—urinary bladder cancer	0.000282	0.00272	CcSEcCtD
Trisalicylate-choline—Pain—Fluorouracil—urinary bladder cancer	0.000282	0.00272	CcSEcCtD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000277	0.0091	CbGpPWpGaD
Trisalicylate-choline—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000277	0.00267	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000276	0.00266	CcSEcCtD
Trisalicylate-choline—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000276	0.00266	CcSEcCtD
Trisalicylate-choline—Anorexia—Etoposide—urinary bladder cancer	0.000273	0.00263	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Thiotepa—urinary bladder cancer	0.000273	0.00263	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Cisplatin—urinary bladder cancer	0.000272	0.00262	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000272	0.00262	CcSEcCtD
Trisalicylate-choline—Drowsiness—Methotrexate—urinary bladder cancer	0.000269	0.00259	CcSEcCtD
Trisalicylate-choline—Hypotension—Etoposide—urinary bladder cancer	0.000267	0.00258	CcSEcCtD
Trisalicylate-choline—Pain—Cisplatin—urinary bladder cancer	0.000267	0.00258	CcSEcCtD
Trisalicylate-choline—Dizziness—Thiotepa—urinary bladder cancer	0.000263	0.00254	CcSEcCtD
Trisalicylate-choline—Urticaria—Fluorouracil—urinary bladder cancer	0.000262	0.00252	CcSEcCtD
Trisalicylate-choline—Asthma—Doxorubicin—urinary bladder cancer	0.000261	0.00252	CcSEcCtD
Trisalicylate-choline—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000261	0.00857	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000259	0.0085	CbGpPWpGaD
Trisalicylate-choline—Sweating—Methotrexate—urinary bladder cancer	0.000258	0.00249	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000257	0.00248	CcSEcCtD
Trisalicylate-choline—Weight increased—Epirubicin—urinary bladder cancer	0.000257	0.00248	CcSEcCtD
Trisalicylate-choline—Somnolence—Etoposide—urinary bladder cancer	0.000254	0.00245	CcSEcCtD
Trisalicylate-choline—Epistaxis—Methotrexate—urinary bladder cancer	0.000254	0.00245	CcSEcCtD
Trisalicylate-choline—Vomiting—Thiotepa—urinary bladder cancer	0.000253	0.00244	CcSEcCtD
Trisalicylate-choline—Drowsiness—Epirubicin—urinary bladder cancer	0.000252	0.00243	CcSEcCtD
Trisalicylate-choline—Rash—Thiotepa—urinary bladder cancer	0.000251	0.00242	CcSEcCtD
Trisalicylate-choline—Dermatitis—Thiotepa—urinary bladder cancer	0.000251	0.00242	CcSEcCtD
Trisalicylate-choline—Headache—Thiotepa—urinary bladder cancer	0.00025	0.00241	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Etoposide—urinary bladder cancer	0.000249	0.0024	CcSEcCtD
Trisalicylate-choline—Constipation—Etoposide—urinary bladder cancer	0.000245	0.00236	CcSEcCtD
Trisalicylate-choline—Pain—Etoposide—urinary bladder cancer	0.000245	0.00236	CcSEcCtD
Trisalicylate-choline—Hepatitis—Methotrexate—urinary bladder cancer	0.000241	0.00233	CcSEcCtD
Trisalicylate-choline—Sweating—Epirubicin—urinary bladder cancer	0.000241	0.00233	CcSEcCtD
Trisalicylate-choline—Weight increased—Doxorubicin—urinary bladder cancer	0.000238	0.00229	CcSEcCtD
Trisalicylate-choline—Epistaxis—Epirubicin—urinary bladder cancer	0.000237	0.00229	CcSEcCtD
Trisalicylate-choline—Pruritus—Gemcitabine—urinary bladder cancer	0.000237	0.00229	CcSEcCtD
Trisalicylate-choline—Nausea—Thiotepa—urinary bladder cancer	0.000237	0.00228	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Etoposide—urinary bladder cancer	0.000236	0.00227	CcSEcCtD
Trisalicylate-choline—Pruritus—Fluorouracil—urinary bladder cancer	0.000233	0.00225	CcSEcCtD
Trisalicylate-choline—Drowsiness—Doxorubicin—urinary bladder cancer	0.000233	0.00224	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000229	0.00221	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000229	0.00752	CbGpPWpGaD
Trisalicylate-choline—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000228	0.0022	CcSEcCtD
Trisalicylate-choline—Urticaria—Etoposide—urinary bladder cancer	0.000227	0.00219	CcSEcCtD
Trisalicylate-choline—Hepatitis—Epirubicin—urinary bladder cancer	0.000226	0.00218	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000225	0.00217	CcSEcCtD
Trisalicylate-choline—Tinnitus—Methotrexate—urinary bladder cancer	0.000225	0.00217	CcSEcCtD
Trisalicylate-choline—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000225	0.00739	CbGpPWpGaD
Trisalicylate-choline—Sweating—Doxorubicin—urinary bladder cancer	0.000223	0.00215	CcSEcCtD
Trisalicylate-choline—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.00022	0.00723	CbGpPWpGaD
Trisalicylate-choline—Epistaxis—Doxorubicin—urinary bladder cancer	0.00022	0.00212	CcSEcCtD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000219	0.0072	CbGpPWpGaD
Trisalicylate-choline—Dizziness—Fluorouracil—urinary bladder cancer	0.000218	0.0021	CcSEcCtD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000215	0.00706	CbGpPWpGaD
Trisalicylate-choline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000214	0.00206	CcSEcCtD
Trisalicylate-choline—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000213	0.00206	CcSEcCtD
Trisalicylate-choline—Vomiting—Gemcitabine—urinary bladder cancer	0.000213	0.00206	CcSEcCtD
Trisalicylate-choline—Rash—Gemcitabine—urinary bladder cancer	0.000211	0.00204	CcSEcCtD
Trisalicylate-choline—Dermatitis—Gemcitabine—urinary bladder cancer	0.000211	0.00204	CcSEcCtD
Trisalicylate-choline—Tinnitus—Epirubicin—urinary bladder cancer	0.000211	0.00203	CcSEcCtD
Trisalicylate-choline—Erythema—Methotrexate—urinary bladder cancer	0.00021	0.00203	CcSEcCtD
Trisalicylate-choline—Headache—Gemcitabine—urinary bladder cancer	0.00021	0.00202	CcSEcCtD
Trisalicylate-choline—Flushing—Epirubicin—urinary bladder cancer	0.00021	0.00202	CcSEcCtD
Trisalicylate-choline—Vomiting—Fluorouracil—urinary bladder cancer	0.00021	0.00202	CcSEcCtD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000209	0.00687	CbGpPWpGaD
Trisalicylate-choline—Hepatitis—Doxorubicin—urinary bladder cancer	0.000209	0.00202	CcSEcCtD
Trisalicylate-choline—Rash—Fluorouracil—urinary bladder cancer	0.000208	0.002	CcSEcCtD
Trisalicylate-choline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000208	0.002	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000207	0.00679	CbGpPWpGaD
Trisalicylate-choline—Headache—Fluorouracil—urinary bladder cancer	0.000206	0.00199	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000206	0.00198	CcSEcCtD
Trisalicylate-choline—Pruritus—Etoposide—urinary bladder cancer	0.000202	0.00195	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000201	0.00659	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.0002	0.00656	CbGpPWpGaD
Trisalicylate-choline—Nausea—Gemcitabine—urinary bladder cancer	0.000199	0.00192	CcSEcCtD
Trisalicylate-choline—Vomiting—Cisplatin—urinary bladder cancer	0.000199	0.00192	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000198	0.0065	CbGpPWpGaD
Trisalicylate-choline—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000198	0.00191	CcSEcCtD
Trisalicylate-choline—Rash—Cisplatin—urinary bladder cancer	0.000197	0.0019	CcSEcCtD
Trisalicylate-choline—Dermatitis—Cisplatin—urinary bladder cancer	0.000197	0.0019	CcSEcCtD
Trisalicylate-choline—Erythema—Epirubicin—urinary bladder cancer	0.000197	0.0019	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Etoposide—urinary bladder cancer	0.000196	0.00189	CcSEcCtD
Trisalicylate-choline—Nausea—Fluorouracil—urinary bladder cancer	0.000196	0.00189	CcSEcCtD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000195	0.00641	CbGpPWpGaD
Trisalicylate-choline—Tinnitus—Doxorubicin—urinary bladder cancer	0.000195	0.00188	CcSEcCtD
Trisalicylate-choline—Flushing—Doxorubicin—urinary bladder cancer	0.000194	0.00187	CcSEcCtD
Trisalicylate-choline—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000194	0.00636	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000193	0.00634	CbGpPWpGaD
Trisalicylate-choline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000192	0.00186	CcSEcCtD
Trisalicylate-choline—Dizziness—Etoposide—urinary bladder cancer	0.000189	0.00183	CcSEcCtD
Trisalicylate-choline—Nausea—Cisplatin—urinary bladder cancer	0.000186	0.00179	CcSEcCtD
Trisalicylate-choline—Vomiting—Etoposide—urinary bladder cancer	0.000182	0.00175	CcSEcCtD
Trisalicylate-choline—Erythema—Doxorubicin—urinary bladder cancer	0.000182	0.00175	CcSEcCtD
Trisalicylate-choline—Rash—Etoposide—urinary bladder cancer	0.00018	0.00174	CcSEcCtD
Trisalicylate-choline—Dermatitis—Etoposide—urinary bladder cancer	0.00018	0.00174	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.00018	0.00591	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.00018	0.00591	CbGpPWpGaD
Trisalicylate-choline—Headache—Etoposide—urinary bladder cancer	0.000179	0.00173	CcSEcCtD
Trisalicylate-choline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000178	0.00172	CcSEcCtD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000174	0.00572	CbGpPWpGaD
Trisalicylate-choline—Confusional state—Methotrexate—urinary bladder cancer	0.000173	0.00167	CcSEcCtD
Trisalicylate-choline—Nausea—Etoposide—urinary bladder cancer	0.00017	0.00164	CcSEcCtD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000166	0.00545	CbGpPWpGaD
Trisalicylate-choline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000166	0.0016	CcSEcCtD
Trisalicylate-choline—Anorexia—Methotrexate—urinary bladder cancer	0.000163	0.00158	CcSEcCtD
Trisalicylate-choline—Confusional state—Epirubicin—urinary bladder cancer	0.000162	0.00156	CcSEcCtD
Trisalicylate-choline—Oedema—Epirubicin—urinary bladder cancer	0.00016	0.00155	CcSEcCtD
Trisalicylate-choline—Hypotension—Methotrexate—urinary bladder cancer	0.00016	0.00154	CcSEcCtD
Trisalicylate-choline—Shock—Epirubicin—urinary bladder cancer	0.000158	0.00152	CcSEcCtD
Trisalicylate-choline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000155	0.0015	CcSEcCtD
Trisalicylate-choline—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000155	0.00508	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000153	0.00503	CbGpPWpGaD
Trisalicylate-choline—Anorexia—Epirubicin—urinary bladder cancer	0.000153	0.00147	CcSEcCtD
Trisalicylate-choline—Somnolence—Methotrexate—urinary bladder cancer	0.000152	0.00147	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000151	0.00496	CbGpPWpGaD
Trisalicylate-choline—Dyspepsia—Methotrexate—urinary bladder cancer	0.000151	0.00146	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.00015	0.00493	CbGpPWpGaD
Trisalicylate-choline—Hypotension—Epirubicin—urinary bladder cancer	0.00015	0.00145	CcSEcCtD
Trisalicylate-choline—Confusional state—Doxorubicin—urinary bladder cancer	0.00015	0.00144	CcSEcCtD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000149	0.0049	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000149	0.00489	CbGpPWpGaD
Trisalicylate-choline—Decreased appetite—Methotrexate—urinary bladder cancer	0.000149	0.00144	CcSEcCtD
Trisalicylate-choline—Oedema—Doxorubicin—urinary bladder cancer	0.000148	0.00143	CcSEcCtD
Trisalicylate-choline—Pain—Methotrexate—urinary bladder cancer	0.000147	0.00141	CcSEcCtD
Trisalicylate-choline—Shock—Doxorubicin—urinary bladder cancer	0.000146	0.00141	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000144	0.00472	CbGpPWpGaD
Trisalicylate-choline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000143	0.00138	CcSEcCtD
Trisalicylate-choline—Somnolence—Epirubicin—urinary bladder cancer	0.000143	0.00138	CcSEcCtD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000142	0.00468	CbGpPWpGaD
Trisalicylate-choline—PTGS1—prostate gland—urinary bladder cancer	0.000142	0.0904	CbGeAlD
Trisalicylate-choline—Anorexia—Doxorubicin—urinary bladder cancer	0.000141	0.00136	CcSEcCtD
Trisalicylate-choline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000141	0.00136	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Epirubicin—urinary bladder cancer	0.000141	0.00136	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000139	0.00134	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000139	0.00457	CbGpPWpGaD
Trisalicylate-choline—Hypotension—Doxorubicin—urinary bladder cancer	0.000139	0.00134	CcSEcCtD
Trisalicylate-choline—Pain—Epirubicin—urinary bladder cancer	0.000137	0.00132	CcSEcCtD
Trisalicylate-choline—Constipation—Epirubicin—urinary bladder cancer	0.000137	0.00132	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000137	0.00449	CbGpPWpGaD
Trisalicylate-choline—Urticaria—Methotrexate—urinary bladder cancer	0.000136	0.00131	CcSEcCtD
Trisalicylate-choline—PTGS2—prostate gland—urinary bladder cancer	0.000135	0.0864	CbGeAlD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000133	0.00436	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000132	0.00127	CcSEcCtD
Trisalicylate-choline—Somnolence—Doxorubicin—urinary bladder cancer	0.000132	0.00127	CcSEcCtD
Trisalicylate-choline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000131	0.00126	CcSEcCtD
Trisalicylate-choline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000129	0.00124	CcSEcCtD
Trisalicylate-choline—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000128	0.0042	CbGpPWpGaD
Trisalicylate-choline—Urticaria—Epirubicin—urinary bladder cancer	0.000127	0.00123	CcSEcCtD
Trisalicylate-choline—Constipation—Doxorubicin—urinary bladder cancer	0.000127	0.00122	CcSEcCtD
Trisalicylate-choline—Pain—Doxorubicin—urinary bladder cancer	0.000127	0.00122	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000124	0.00407	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000123	0.00404	CbGpPWpGaD
Trisalicylate-choline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000122	0.00118	CcSEcCtD
Trisalicylate-choline—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000122	0.004	CbGpPWpGaD
Trisalicylate-choline—Pruritus—Methotrexate—urinary bladder cancer	0.000121	0.00117	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000121	0.00397	CbGpPWpGaD
Trisalicylate-choline—PTGS1—seminal vesicle—urinary bladder cancer	0.00012	0.0765	CbGeAlD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000119	0.00391	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000119	0.00389	CbGpPWpGaD
Trisalicylate-choline—Urticaria—Doxorubicin—urinary bladder cancer	0.000118	0.00114	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Methotrexate—urinary bladder cancer	0.000117	0.00113	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000116	0.00382	CbGpPWpGaD
Trisalicylate-choline—PTGS2—seminal vesicle—urinary bladder cancer	0.000115	0.0731	CbGeAlD
Trisalicylate-choline—Pruritus—Epirubicin—urinary bladder cancer	0.000113	0.00109	CcSEcCtD
Trisalicylate-choline—Dizziness—Methotrexate—urinary bladder cancer	0.000113	0.00109	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000111	0.00364	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.00011	0.00361	CbGpPWpGaD
Trisalicylate-choline—Diarrhoea—Epirubicin—urinary bladder cancer	0.00011	0.00106	CcSEcCtD
Trisalicylate-choline—Vomiting—Methotrexate—urinary bladder cancer	0.000109	0.00105	CcSEcCtD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000109	0.00356	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000108	0.00355	CbGpPWpGaD
Trisalicylate-choline—Rash—Methotrexate—urinary bladder cancer	0.000108	0.00104	CcSEcCtD
Trisalicylate-choline—Dermatitis—Methotrexate—urinary bladder cancer	0.000108	0.00104	CcSEcCtD
Trisalicylate-choline—Headache—Methotrexate—urinary bladder cancer	0.000107	0.00104	CcSEcCtD
Trisalicylate-choline—Dizziness—Epirubicin—urinary bladder cancer	0.000106	0.00102	CcSEcCtD
Trisalicylate-choline—Pruritus—Doxorubicin—urinary bladder cancer	0.000105	0.00101	CcSEcCtD
Trisalicylate-choline—PTGS1—epithelium—urinary bladder cancer	0.000104	0.0664	CbGeAlD
Trisalicylate-choline—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.000104	0.00341	CbGpPWpGaD
Trisalicylate-choline—Vomiting—Epirubicin—urinary bladder cancer	0.000102	0.000984	CcSEcCtD
Trisalicylate-choline—Nausea—Methotrexate—urinary bladder cancer	0.000102	0.000982	CcSEcCtD
Trisalicylate-choline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000102	0.000979	CcSEcCtD
Trisalicylate-choline—Rash—Epirubicin—urinary bladder cancer	0.000101	0.000976	CcSEcCtD
Trisalicylate-choline—Dermatitis—Epirubicin—urinary bladder cancer	0.000101	0.000975	CcSEcCtD
Trisalicylate-choline—Headache—Epirubicin—urinary bladder cancer	0.0001	0.000969	CcSEcCtD
Trisalicylate-choline—PTGS1—smooth muscle tissue—urinary bladder cancer	0.0001	0.064	CbGeAlD
Trisalicylate-choline—PTGS2—epithelium—urinary bladder cancer	9.95e-05	0.0635	CbGeAlD
Trisalicylate-choline—Dizziness—Doxorubicin—urinary bladder cancer	9.82e-05	0.000947	CcSEcCtD
Trisalicylate-choline—PTGS1—renal system—urinary bladder cancer	9.66e-05	0.0616	CbGeAlD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.61e-05	0.00316	CbGpPWpGaD
Trisalicylate-choline—PTGS2—smooth muscle tissue—urinary bladder cancer	9.59e-05	0.0612	CbGeAlD
Trisalicylate-choline—Nausea—Epirubicin—urinary bladder cancer	9.53e-05	0.000919	CcSEcCtD
Trisalicylate-choline—Vomiting—Doxorubicin—urinary bladder cancer	9.44e-05	0.00091	CcSEcCtD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.44e-05	0.0031	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	9.41e-05	0.00309	CbGpPWpGaD
Trisalicylate-choline—Rash—Doxorubicin—urinary bladder cancer	9.36e-05	0.000903	CcSEcCtD
Trisalicylate-choline—Dermatitis—Doxorubicin—urinary bladder cancer	9.35e-05	0.000902	CcSEcCtD
Trisalicylate-choline—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.35e-05	0.00307	CbGpPWpGaD
Trisalicylate-choline—Headache—Doxorubicin—urinary bladder cancer	9.3e-05	0.000897	CcSEcCtD
Trisalicylate-choline—PTGS2—renal system—urinary bladder cancer	9.23e-05	0.0589	CbGeAlD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	9.17e-05	0.00301	CbGpPWpGaD
Trisalicylate-choline—PTGS2—urethra—urinary bladder cancer	9.07e-05	0.0578	CbGeAlD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	8.87e-05	0.00291	CbGpPWpGaD
Trisalicylate-choline—Nausea—Doxorubicin—urinary bladder cancer	8.82e-05	0.00085	CcSEcCtD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	8.54e-05	0.0028	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	8.52e-05	0.0028	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	8.44e-05	0.00277	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.36e-05	0.00275	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	8.31e-05	0.00273	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTO2—urinary bladder cancer	8.08e-05	0.00265	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—NAT1—urinary bladder cancer	8.08e-05	0.00265	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.94e-05	0.00261	CbGpPWpGaD
Trisalicylate-choline—PTGS1—female reproductive system—urinary bladder cancer	7.73e-05	0.0493	CbGeAlD
Trisalicylate-choline—PTGS2—Disease—GSTO2—urinary bladder cancer	7.65e-05	0.00251	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	7.5e-05	0.00246	CbGpPWpGaD
Trisalicylate-choline—PTGS2—female reproductive system—urinary bladder cancer	7.39e-05	0.0472	CbGeAlD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.39e-05	0.00243	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	7.39e-05	0.00243	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.36e-05	0.00242	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	7.35e-05	0.00241	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.33e-05	0.00241	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	7.17e-05	0.00235	CbGpPWpGaD
Trisalicylate-choline—PTGS1—vagina—urinary bladder cancer	7e-05	0.0446	CbGeAlD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	6.99e-05	0.00229	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	6.79e-05	0.00223	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	6.78e-05	0.00223	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	6.76e-05	0.00222	CbGpPWpGaD
Trisalicylate-choline—PTGS2—vagina—urinary bladder cancer	6.69e-05	0.0427	CbGeAlD
Trisalicylate-choline—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	6.65e-05	0.00218	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.6e-05	0.00217	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.42e-05	0.00211	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTO2—urinary bladder cancer	6.41e-05	0.00211	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—NAT1—urinary bladder cancer	6.41e-05	0.00211	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.34e-05	0.00208	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.31e-05	0.00207	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	6.28e-05	0.00206	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PRSS3—urinary bladder cancer	6.12e-05	0.00201	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—SLC19A1—urinary bladder cancer	5.95e-05	0.00195	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	5.86e-05	0.00193	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PRSS3—urinary bladder cancer	5.8e-05	0.00191	CbGpPWpGaD
Trisalicylate-choline—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	5.78e-05	0.0019	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	5.6e-05	0.00184	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HDAC4—urinary bladder cancer	5.53e-05	0.00182	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	5.48e-05	0.0018	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.38e-05	0.00177	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	5.28e-05	0.00173	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	5.22e-05	0.00171	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.99e-05	0.00164	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.91e-05	0.00161	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—TYMP—urinary bladder cancer	4.89e-05	0.00161	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.86e-05	0.0016	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.75e-05	0.00156	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.7e-05	0.00154	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.6e-05	0.00151	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.6e-05	0.00151	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.59e-05	0.00151	CbGpPWpGaD
Trisalicylate-choline—PTGS1—lymph node—urinary bladder cancer	4.52e-05	0.0289	CbGeAlD
Trisalicylate-choline—PTGS1—Metabolism—NAT2—urinary bladder cancer	4.42e-05	0.00145	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—LIG1—urinary bladder cancer	4.4e-05	0.00144	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.37e-05	0.00144	CbGpPWpGaD
Trisalicylate-choline—PTGS2—lymph node—urinary bladder cancer	4.32e-05	0.0276	CbGeAlD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.25e-05	0.0014	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.9e-05	0.00128	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.88e-05	0.00128	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.82e-05	0.00125	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.81e-05	0.00125	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.73e-05	0.00123	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.73e-05	0.00122	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.55e-05	0.00117	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.54e-05	0.00116	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.54e-05	0.00116	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.52e-05	0.00116	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.52e-05	0.00115	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.51e-05	0.00115	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.43e-05	0.00113	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.38e-05	0.00111	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ENO2—urinary bladder cancer	3.35e-05	0.0011	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—RBX1—urinary bladder cancer	3.18e-05	0.00104	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.13e-05	0.00103	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.03e-05	0.000996	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.85e-05	0.000936	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—JAG1—urinary bladder cancer	2.85e-05	0.000934	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.81e-05	0.000922	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.81e-05	0.000922	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.79e-05	0.000917	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.77e-05	0.000908	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.72e-05	0.000894	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.68e-05	0.000881	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.41e-05	0.000792	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.38e-05	0.000781	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.3e-05	0.000756	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.26e-05	0.000743	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.21e-05	0.000726	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.19e-05	0.000718	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.19e-05	0.000718	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.09e-05	0.000687	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—NCOR1—urinary bladder cancer	2.07e-05	0.00068	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.05e-05	0.000675	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ERCC2—urinary bladder cancer	1.95e-05	0.00064	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.93e-05	0.000634	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.92e-05	0.000629	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.89e-05	0.00062	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—MTHFR—urinary bladder cancer	1.83e-05	0.000601	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.83e-05	0.0006	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—TERT—urinary bladder cancer	1.83e-05	0.0006	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.76e-05	0.000576	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.73e-05	0.00057	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.73e-05	0.00057	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—FGFR3—urinary bladder cancer	1.68e-05	0.00055	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.66e-05	0.000546	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.63e-05	0.000536	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.57e-05	0.000514	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.53e-05	0.000504	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.5e-05	0.000494	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CREBBP—urinary bladder cancer	1.43e-05	0.000468	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—RHOA—urinary bladder cancer	1.29e-05	0.000424	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.24e-05	0.000408	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	0.000405	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.19e-05	0.000392	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—ERBB2—urinary bladder cancer	1.19e-05	0.000392	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.07e-05	0.000353	CbGpPWpGaD
Trisalicylate-choline—PTGS1—Metabolism—EP300—urinary bladder cancer	1.02e-05	0.000336	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.02e-05	0.000335	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—PTEN—urinary bladder cancer	1.02e-05	0.000334	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—EP300—urinary bladder cancer	9.71e-06	0.000319	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—SRC—urinary bladder cancer	9.45e-06	0.00031	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—PTEN—urinary bladder cancer	8.53e-06	0.00028	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—MYC—urinary bladder cancer	8.46e-06	0.000278	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—EGFR—urinary bladder cancer	8.28e-06	0.000272	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Metabolism—EP300—urinary bladder cancer	8.13e-06	0.000267	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—KRAS—urinary bladder cancer	7.82e-06	0.000257	CbGpPWpGaD
Trisalicylate-choline—PTGS2—Disease—HRAS—urinary bladder cancer	6.65e-06	0.000218	CbGpPWpGaD
